ArticlebioRxiv : the preprint server for biology2026
Preparation and application of YFV-17D-derived Anterograde Trans-neuronal Viral Vectors for Neuroscience Research.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Trans-neuronal viruses that spread between synaptically connected neurons have become invaluable tools in neuroscience, enabling circuit mapping and targeted delivery of genetic material to cells within defined pathways. Although most available trans-neuronal viral tracers propagate retrogradely, an anterograde trans-neuronal virus that spread from presynaptic to postsynaptic neurons would substantially expand experimental capabilities. We previously demonstrated that YFV-17D-a live attenuated yellow fever vaccine used clinically for decades-spreads anterogradely along neuronal circuits. We further developed a suite of recombinant YFV-17D-based vectors for diverse applications, including tracing monosynaptic projectome of defined neuronal cell types, multiplex mapping of parallel pathways, and trans-neuronal genetic manipulation with minimal neurotoxicity. We have now tested and optimized procedures for vector production and application. Based on these optimizations, here, we present a two-part guide for preparing and deploying this viral vector system to map brain connectivity. The first part describes the molecular biology and cell culture workflows required to generate high-quality viral vectors, yielding titers of ~1 × 10^10 to 5 × 10^11 genomic copies per milliliter within approximately two weeks. The second part outlines optimized animal procedures, including intracranial injections, perioperative care, and experimental considerations tailored to specific aims and vector variants. Depending on the application, efficient trans-neuronal tracing can be achieved within 1-4 weeks following delivery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.